Part­nered with Genen­tech and Mi­crosoft, this biotech be­lieves it can lever­age its knowl­edge of the im­mune sys­tem in­to a $230M-plus IPO

Broth­ers Chad and Har­lan Robins love big names, big num­bers and big plans. And it’s all on big dis­play in their new­ly filed S-1 for Adap­tive Biotech­nolo­gies, which out­lines a plan to lever­age its work on can­cer neoanti­gens and di­ag­nos­tics in­to a whop­ping $230 mil­lion-plus IPO.

We’ve been see­ing a wave of new IPO fil­ings hit this mar­ket in the last few weeks, with some mixed but over­all en­cour­ag­ing re­spons­es from in­vestors. Along­side Adap­tive, Mor­phic Ther­a­peu­tics in the boom­ing Cam­bridge/Boston hub has al­so de­cid­ed to make the leap in­to the pub­lic mar­ket, post­ing an S-1 with an in­dus­try-stan­dard $86 mil­lion raise pen­ciled in as they hunt their next big in­jec­tion of cap­i­tal. Helmed by well-known biotech ex­ec Praveen Tipir­neni, the biotech has been build­ing a plat­form based on work out of the lab of Har­vard’s Tim Springer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER